Understanding patient experiences with buprenorphine treatment for opioid use disorder
Exploring the Attitudes and Experiences of Patients Engaged in Buprenorphine Treatment During the COVID-19 Pandemic
Cambridge Health Alliance · NCT05121428
This study is trying to learn about how people feel and what they experience while using buprenorphine for opioid addiction during the COVID-19 pandemic.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Cambridge Health Alliance (other) |
| Locations | 1 site (Cambridge, Massachusetts) |
| Trial ID | NCT05121428 on ClinicalTrials.gov |
What this trial studies
This observational study aims to gather insights into patients' attitudes and experiences while receiving buprenorphine treatment for opioid use disorder during the COVID-19 pandemic. It will utilize five surveys to evaluate various aspects, including the impact of telemedicine on access to treatment, motivations for abstaining from opioid use, and the use of other substances like cannabis and benzodiazepines. The study seeks to understand how these factors have changed during the pandemic and how they relate to patients' overall treatment experiences.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have a legal prescription for buprenorphine and a history of opioid use disorder, residing in Massachusetts.
Not a fit: Patients who do not have a prescription for buprenorphine or those unable to complete online surveys may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of patient needs and improve treatment approaches for opioid use disorder.
How similar studies have performed: While there have been studies on opioid treatment, this specific focus on patient attitudes during the pandemic is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants must be 18 years of age or older. * Participants report currently having a legal prescription for buprenorphine for opioid use disorder. * Participants must have a past or present opioid use disorder. * Participants must currently reside in the state of Massachusetts. * Participants must be able to comprehend the English language. Exclusion Criteria: * Unable to complete an online survey. * Unable to complete a verification step that ensures bots are not used to complete survey. * Complete a survey with no variation suggesting they did not read the survey.
Where this trial is running
Cambridge, Massachusetts
- CHA Center for Mindfulness and Compassion — Cambridge, Massachusetts, United States (RECRUITING)
Study contacts
- Principal investigator: Zev Schuman-Olivier, MD — Cambridge Health Alliance
- Study coordinator: Joseph Rosansky
- Email: jrosansky@cha.harvard.edu
- Phone: 617-575-5802
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Opioid-use Disorder, Acceptability of Health Care, Opioid-Related Disorders, Opioid Use Disorder, Substance Use Disorders, Buprenorphine, Suboxone, Cannabis